![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: INTS7 |
Gene summary for INTS7 |
![]() |
Gene information | Species | Human | Gene symbol | INTS7 | Gene ID | 25896 |
Gene name | integrator complex subunit 7 | |
Gene Alias | C1orf73 | |
Cytomap | 1q32.3 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q9NVH2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25896 | INTS7 | CCI_1 | Human | Cervix | CC | 7.40e-10 | 6.58e-01 | 0.528 |
25896 | INTS7 | CCI_2 | Human | Cervix | CC | 4.06e-04 | 5.02e-01 | 0.5249 |
25896 | INTS7 | CCI_3 | Human | Cervix | CC | 3.27e-06 | 6.27e-01 | 0.516 |
25896 | INTS7 | HCC1_Meng | Human | Liver | HCC | 3.73e-43 | 3.33e-02 | 0.0246 |
25896 | INTS7 | HCC2_Meng | Human | Liver | HCC | 4.12e-04 | 4.60e-03 | 0.0107 |
25896 | INTS7 | HCC2 | Human | Liver | HCC | 1.59e-05 | 2.95e+00 | 0.5341 |
25896 | INTS7 | HCC5 | Human | Liver | HCC | 2.69e-03 | 1.03e+00 | 0.4932 |
25896 | INTS7 | S028 | Human | Liver | HCC | 3.40e-03 | 3.52e-01 | 0.2503 |
25896 | INTS7 | S029 | Human | Liver | HCC | 3.80e-03 | 3.60e-01 | 0.2581 |
25896 | INTS7 | HTA12-23-1 | Human | Pancreas | PDAC | 5.63e-04 | 5.93e-01 | 0.3405 |
25896 | INTS7 | HTA12-26-1 | Human | Pancreas | PDAC | 1.95e-08 | 5.14e-01 | 0.3728 |
25896 | INTS7 | HTA12-29-1 | Human | Pancreas | PDAC | 3.15e-23 | 5.83e-01 | 0.3722 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007147921 | Liver | HCC | cellular response to ionizing radiation | 47/7958 | 72/18723 | 7.95e-05 | 7.07e-04 | 47 |
GO:00714782 | Liver | HCC | cellular response to radiation | 104/7958 | 186/18723 | 1.48e-04 | 1.19e-03 | 104 |
GO:00000771 | Liver | HCC | DNA damage checkpoint | 68/7958 | 115/18723 | 2.33e-04 | 1.77e-03 | 68 |
GO:0031570 | Liver | HCC | DNA integrity checkpoint | 71/7958 | 123/18723 | 4.64e-04 | 3.08e-03 | 71 |
GO:1901988 | Liver | HCC | negative regulation of cell cycle phase transition | 132/7958 | 249/18723 | 4.97e-04 | 3.25e-03 | 132 |
GO:0010948 | Liver | HCC | negative regulation of cell cycle process | 152/7958 | 294/18723 | 8.50e-04 | 5.08e-03 | 152 |
GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INTS7 | SNV | Missense_Mutation | novel | c.2626N>C | p.Glu876Gln | p.E876Q | Q9NVH2 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
INTS7 | SNV | Missense_Mutation | novel | c.2552N>C | p.Cys851Ser | p.C851S | Q9NVH2 | protein_coding | tolerated(0.25) | probably_damaging(0.985) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |
INTS7 | SNV | Missense_Mutation | c.2207N>A | p.Gly736Glu | p.G736E | Q9NVH2 | protein_coding | tolerated(0.69) | probably_damaging(0.999) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
INTS7 | SNV | Missense_Mutation | novel | c.319N>T | p.Ile107Phe | p.I107F | Q9NVH2 | protein_coding | deleterious(0) | benign(0.103) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
INTS7 | SNV | Missense_Mutation | novel | c.2501N>C | p.Val834Ala | p.V834A | Q9NVH2 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
INTS7 | SNV | Missense_Mutation | c.1741N>A | p.Glu581Lys | p.E581K | Q9NVH2 | protein_coding | tolerated(0.73) | benign(0.022) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
INTS7 | SNV | Missense_Mutation | c.802N>A | p.Val268Ile | p.V268I | Q9NVH2 | protein_coding | tolerated(0.2) | benign(0.104) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
INTS7 | SNV | Missense_Mutation | c.1616N>G | p.His539Arg | p.H539R | Q9NVH2 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
INTS7 | SNV | Missense_Mutation | novel | c.2221N>A | p.Asp741Asn | p.D741N | Q9NVH2 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-EW-A6SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tch | SD |
INTS7 | SNV | Missense_Mutation | novel | c.1965G>A | p.Met655Ile | p.M655I | Q9NVH2 | protein_coding | tolerated(0.49) | benign(0.025) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |